Navigation Links
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Date:9/7/2007

5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

Conventional, approved Xeloda dosing on a 14-on/7-off schedule is 1250 mg/m(2) twice daily (total of 2500 mg/m(2)/day).

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... Top-line Data Expected in August -, EXTON, ... today the completion of the pivotal efficacy portion ... Isolagen,Therapy(TM) for the treatment of nasolabial folds, or ... the primary efficacy follow-up visit,and collation of this ...
... ... Professionals, VOORHEES, N.J., July 1 ... a wide spectrum of,severity, ranging from mild diarrhea to pseudomembranous colitis ... who develop an initial,case of CDI.(1) These patients are at increased ...
Cached Medicine Technology:Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 2Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
(Date:6/30/2015)... ... June 30, 2015 , ... CCAR is pleased to announce its ... in Hartford, Willimantic and Bridgeport. This month, staff member Jim Higgins left his ... He is excited to take on this role of organizing peer recovery support ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, ... ... Physicians News Digest discussed the advantages that fat transfer procedures had ... breast reconstruction using fat transfer techniques create breasts that “look and feel natural,” ...
(Date:6/30/2015)... GA (PRWEB) , ... June 30, 2015 , ... After ... by the U.S. Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for ... with an SPF rating of 35, hits the market just in time to help ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... response profiling test to help oncologists provide personalized cancer treatment, will be ... assay provides the oncologist with valuable insight on how a specific patient’s ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... medical device market research, has launched a new reimbursement insurance policy tracking and ... professionals to receive US insurance policy and rate updates in real-time from hundreds ...
Breaking Medicine News(10 mins):Health News:The Connecticut Community for Addiction Recovery takes Recovery Coaching to a new level 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2
... Fla., Jan. 7 - 3M, in,partnership with Roush Fenway Racing, ... paint scheme to the American Red Cross for two races,during ... space on the,rear side panel of the car where the ... year., (Photo: http://www.newscom.com/cgi-bin/prnh/20080107/DC10974 ), "This is ...
... WellPoint, Inc. (NYSE: WLP ) today,announced that ... Technology,and Government Services Business Unit, has been recognized ... Computerworld,s 2008 Premier 100 honors the 100 ... and motivating employees; envisioning,innovative solutions to business challenges; ...
... 7 Barc, the leader in the $1.8 billion,African-American ... of its new travel size for its market leading ... product is now available,in a convenient 1.7 oz bottle ... reduces irritation and ingrown hairs due to shaving,preventing new ...
... cells and cancer stem cells reveals that the cancer ... of development. The research, published by Cell Press in ... understanding of glioma pathophysiology and provides new directions for ... types of tumors. , Tumor-initiating cells with stem like ...
... COLUMBUS , Ohio New research suggests that at any ... (EMTs) and paramedics in the United States miss work because ... , A study examining how common these injuries are and ... professionals also suggests that in one year, an estimated 8.1 ...
... less food had same effect on weight at age 2, study ... toddlers consume, either by trying to get them to eat less ... weight by the age of 2, new British research suggests. , ... always in the best interest of a young child, according to ...
Cached Medicine News:Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 2Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 3Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 2Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 3Health News:Forever young: Differentiation blocked in tumor stem cells 2Health News:Emergency responders at high risk to miss work because of injuries 2Health News:Emergency responders at high risk to miss work because of injuries 3Health News:Parental Control of Eating Leads to Lighter Toddlers 2Health News:Parental Control of Eating Leads to Lighter Toddlers 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: